Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, LOU064, LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet
CLOU064J12303B
Phase 3 small_molecule active
Quick answer
Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, LOU064, LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet for Hidradenitis Suppurativa (HS) is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Hidradenitis Suppurativa (HS)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active